Stock Code: 600380 Stock Short Name: 健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2022 Third Quarterly Report
The Board of Directors and all Directors of the Company hereby warrant that thereare no false representations, misleading statements or material omissions contained inthis announcement and accept legal responsibility for the truthfulness, accuracy andcompleteness of the contents hereof.
IMPORTANT NOTICE:
? The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior managementof the Company hereby warrant the truthfulness, accuracy and completeness of the contents of thisquarterly report, and that there are no false representations, misleading statements or materialomissions contained herein, and severally and jointly accept legal responsibility.
? The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-charge of the accounting department (the head of the accounting department) hereby warrant thetruthfulness, accuracy and completeness of the financial information contained in this quarterly report.
? Whether the third quarterly financial statements are audited.
□Yes √No
I. MAJOR FINANCIAL DATA(I) Major Accounting Date and Financial Indicators
Unit: Yuan Currency: RMB
| Item | For the Reporting Period | YoY change (%) | From the beginning of the year to the end of the Reporting Period | YoY change (%) |
| Revenue | 4,447,021,452.61 | 8.51 | 13,011,966,738.16 | 9.04 |
| Net profit attributable to shareholders of the listed company | 325,293,433.73 | 1.23 | 1,126,561,953.23 | 11.69 |
| Net profit attributable to shareholders of the listed company after deduction of extraordinary gains and losses | 312,360,089.27 | -2.90 | 1,116,354,521.30 | 21.40 |
| Net cash flow from operating activities | N/A | N/A | 2,608,992,532.97 | 60.93 |
| Basic earnings per share (RMB/share) | 0.1748 | 6.61 | 0.5983 | 16.09 |
| Diluted earnings per share (RMB/share) | 0.1739 | 6.19 | 0.5971 | 16.13 |
| Weighted average return on net assets (%) | 2.74 | Decreased by 0.11 percentage points | 9.39 | Increased by 0.50 percentage points |
| As at the end of the Reporting Period | As at the end of the previous year | YoY change (%) | ||
| Total assets | 34,713,695,364.54 | 31,103,900,389.29 | 11.61 | |
| Owner's equity attributable to shareholders of the listed company | 12,900,492,209.56 | 11,820,293,656.69 | 9.14 | |
Notes: 1. The “Reporting Period” represents the 3-month period from the beginning to the end of this quarter,the same below.
2. From July to September 2022, the Company realized net profit attributable to shareholders of theparent of RMB325 million, of which Joincare excluding Livzon Pharmaceutical Group Inc. (“Livzon Group”)and Livzon MAB Pharm Inc. (“Livzon MAB”) realized net profit attributable to shareholders of the parent ofapproximately RMB217 million, representing a YoY increase of approximately 37%, and the impact of LivzonMAB on the net profit attributable to shareholders of the parent was approximately negative RMB186 million.From January to September 2022, the Company realized net profit attributable to shareholders of the parent ofRMB1,127 million, of which Joincare (excluding Livzon Group and Livzon MAB) realized net profitattributable to shareholders of the parent of approximately RMB638 million, representing a YoY increase ofapproximately 42%, and the impact of Livzon MAB on the net profit attributable to shareholders of the parentwas approximately negative RMB325 million.
3. From January to September 2022, the Company realized revenue of RMB7,402 million fromchemical pharmaceuticals, representing a YoY increase of 7.16%, among which, RMB862 million were fromrespiratory formulation, representing a YoY increase of 215%; RMB1,151 million were from anti-infectiveproducts, representing a YoY increase of 9.29%; RMB2,646 million were from gastroenterology products,representing a YoY decrease of 11.60%; RMB2,092 million were from gonadotropic hormones, representing aYoY increase of 5.81% and RMB400 million were from psychiatry products, representing a YoY increase of
30.68%. The Company realized revenue of RMB4,054 million from APIs and intermediates, representing aYoY increase of 17.80%. The Company realized revenue of RMB864 million from traditional Chinesemedicine, representing a YoY increase of 1.28%. The Company realized revenue of RMB502 million fromdiagnostic reagents and equipment, representing a YoY decrease of 9.09%. The Company realized revenue ofRMB83 million from health care products, representing a YoY decrease of 4.30%.
(II) Items and Amounts of Extraordinary Gains and Losses
Unit: Yuan Currency: RMB
| Item | For the Reporting Period | From the beginning of the year to the end of the Reporting Period |
| Gain or loss on disposal of non-current assets | 1,429,336.99 | 5,161,222.54 |
| Government grants recognized in profit or loss for the current period (excluding government grants that are closely related to the ordinary operating business of the Company and are provided in fixed amount or quantity continuously according to the applicable polices and standards of the country) | 45,982,790.93 | 140,167,993.52 |
| Gains and losses on fair value changes incurred from financial assets held for trading, derivative financial assets, financial liabilities held for trading and derivative financial liabilities, and investment income on disposal of financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and other debt investments, except for effective hedging activities related to the ordinary operating business of the Company | -14,007,798.34 | -112,944,327.05 |
| Reversal of provision for impairment of accounts receivable and contract assets tested for impairment individually | 0.00 | 158,470.77 |
| Other non-operating income and expenses apart from the above items | -6,269,628.08 | -8,540,320.05 |
| Less: Effect of income tax | -330,154.62 | 10,109,361.17 |
| Effect of minority equity (after tax) | 14,531,511.66 | 3,686,246.63 |
| Total | 12,933,344.46 | 10,207,431.93 |
Explanations for classifying items of extraordinary gains and losses defined in the ExplanatoryAnnouncement No. 1 for Public Company Information Disclosures –Non-recurring Profits and Losses asitems of recurring profit or loss
□Applicable √N/A
(III) Changes in Major Accounting Data and Financial Indicators and Reasons Therefor
√Applicable □N/A
| Item | Change (%) | Main reasons |
| Net cash flow from operating activities | 60.93 | Mainly due to an increase of cash collections of sales revenues. |
(IV) Material Changes in Other Items in Financial Statements and Financial Indicators and ReasonsTherefor
| Balance Sheet | 30 September 2022 | 31 December 2021 | Change in proportion （%） | Main Reason |
| Financial assets held for trading | 121,394,233.59 | 184,638,344.31 | -34.25 | Primarily due to fluctuations in market value of the securities investment held. |
| Other receivables | 51,182,462.61 | 88,053,825.12 | -41.87 | Mainly due to the receipt of payment during the current period. |
| Non-current assets due within one year | 38,498.84 | 317,381.23 | -87.87 | Primarily due to the recovery of finance lease payments. |
| Other current assets | 28,941,853.23 | 83,986,214.37 | -65.54 |
Primarily due to the decrease inthe amount of VAT credits as aresult of the refund thereof andthe prepaid income tax hastransferred out.
| Long-term receivables | 82,574.69 | 266,904.13 | -69.06 | Primarily due to the recovery of finance lease payments. |
| Financial liabilities held for trading | 23,888,725.35 | 143,302.24 | 16570.17 | Primarily due to fluctuations in fair value of foreign exchange forward contract |
| Contract liabilities | 85,390,395.48 | 234,140,702.29 | -63.53 | Primarily due to some contract performance obligations during the current period, which satisfies the conditions for revenue recognition and results in the carrying forward of revenue. |
| Taxes payable | 356,093,489.85 | 270,618,183.41 | 31.59 | Primarily due to the increase in corporate income tax payable. |
| Non-current liabilities due within one year | 19,385,099.93 | 91,576,066.33 | -78.83 | Mainly due to an increase of repayment of long-term borrowings. |
| Other current liabilities | 5,977,716.75 | 15,626,224.29 | -61.75 | Primarily due to the decrease in pending output tax as the contract payment collected in advance in the current period meets the revenue recognition conditions and is carried forward. |
| Long-term loans | 3,028,666,590.94 | 826,780,252.78 | 266.32 | Mainly due to an addition to long-term borrowings during the current period. |
| Other comprehensive income | 37,371,610.95 | 5,387,545.97 | 593.67 | Mainly due to change of exchange differences on translation of statements as a result of fluctuation in exchange rate. |
| Statement of Income | January to September for 2022 | January to September for 2021 | Change in proportion （%） | Main Reason |
| Financial expenses | -330,371,807.68 | -43,302,001.92 | N/A | Mainly due to the deposit interest during the current period is higher than last period and the |
| exchange gains arising from fluctuation in exchange rate. | ||||
| Income from investments (loss is indicated by“-”) | 48,386,584.36 | 69,260,277.50 | -30.14 | Primarily due to a decrease in dividend for the current period, together with fluctuation in exchange rate and losses from settlement of the forward foreign exchange contract business. |
| Gains from changes in fair values (loss is indicated by“-”) | -86,989,533.83 | -18,014,545.96 | N/A | Primarily due to fluctuations in market value of the securities investment held. |
| Impairment loss of assets (loss is indicated by“-”) | -142,159,872.24 | -35,798,711.62 | N/A | Primarily due to the impairment provision for inventories for the current period is higher than last period. |
| Gains from disposal of assets (loss is indicated by“-”) | 1,121,679.66 | 18,357,859.21 | -93.89 | Mainly due to gains from transfer of land use rights during last period. |
| Cash Flow Statement | January to September for 2022 | January to September for 2021 | Change in proportion （%） | Main Reason |
| Net cash flow from operating activities | 2,608,992,532.97 | 1,621,169,704.58 | 60.93 | Mainly due to an increase of cash collections of sales revenues for the current period. |
| Net cash flow from investing activities | -886,929,197.44 | -1,509,334,937.50 | N/A | Mainly due to the combination of cash collection through selling equity and the additional investment for last period. |
| Net cash flow from financing activities | 873,841,344.96 | -1,783,771,890.06 | N/A | Mainly due to the further borrowings and capital raised (issuance of GDRs) for the current period. |
II. SHAREHOLDERS(I) Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with RestoredVoting Rights and Shareholdings of Top 10 Shareholders
Unit: shares
| Total number of holders of ordinary shares as of the end of the Reporting Period | 96,795 | Total number of holders of preferred shares with restored voting rights as of the end of the Reporting Period (if any) | 0 | ||||
| Shareholdings of the top 10 shareholders | |||||||
| Name of shareholder | Nature of shareholder | Number of shares held | Percentage (%) | Number of shares held with selling restrictions | Pledge, mark or lock-up | ||
| Share status | Number | ||||||
| Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源投资有限公司) | Domestic non-state-owned entity | 878,272,753 | 45.56 | 0 | Pledge | 95,679,725 | |
| Hong Kong Securities Clearing Company Limited | Unknown | 130,019,561 | 6.74 | 0 | Unknown | ||
| Citibank, National Association | Unknown | 63,825,000 | 3.31 | 0 | Unknown | ||
| Might Seasons Limited | Foreign entity | 57,487,434 | 2.98 | 0 | Unknown | ||
| Huaxia Life Insurance Co., Ltd. - Own fund | Unknown | 9,275,718 | 0.48 | 0 | Unknown | ||
| He Zhong | Domestic natural person | 7,800,024 | 0.40 | 0 | Unknown | ||
| Abu Dhabi Investment Authority (阿布达比投资局) | Foreign entity | 6,334,742 | 0.33 | 0 | Unknown | ||
| Joincare Pharmaceutical Group Industry Co., Ltd. — the Second Phase Ownership Scheme under Medium to Long-term Business Partner Share Ownership Scheme (健康元药业集团股份有限公司－中长期事业合伙人持股计划之第二期持股计划) | Others | 6,275,372 | 0.33 | 0 | - | ||
| 16011 portfolio of basic endowment insurance fund | Unknown | 5,867,634 | 0.30 | 0 | Unknown | ||
| Agricultural Bank of China Limited - CSI 500 Exchange Traded Index Securities Investment Fund | Unknown | 5,480,994 | 0.28 | 0 | Unknown | ||
| Shareholdings of the top 10 shareholders without selling restrictions | |||||||
| Name of shareholder | Number of tradable shares held without selling restrictions | Class and number of shares | |||||
| Class of shares | Number | ||||||
| Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源投资有限公司) | 878,272,753 | Ordinary shares denominated in Renminbi | 878,272,753 | ||||
| Hong Kong Securities Clearing Company Limited | 130,019,561 | Ordinary shares denominated in Renminbi | 130,019,561 | ||||
| Citibank, National Association | 63,825,000 | Ordinary shares denominated in Renminbi | 63,825,000 | ||||
| Might Seasons Limited | 57,487,434 | Ordinary shares denominated in Renminbi | 57,487,434 | ||||
| Huaxia Life Insurance Co., Ltd. - Own fund | 9,275,718 | Ordinary shares denominated in Renminbi | 9,275,718 | ||||
| He Zhong | 7,800,024 | Ordinary shares denominated in Renminbi | 7,800,024 | ||||
| Abu Dhabi Investment Authority (阿布达比投资局) | 6,334,742 | Ordinary shares denominated in Renminbi | 6,334,742 | ||||
| Joincare Pharmaceutical Group Industry Co., Ltd. — the Second Phase Ownership Scheme under Medium to Long-term Business Partner Share Ownership Scheme (健康元药业集团股份有限公司－中长期事业合伙人持股计划之第二期持股计划) | 6,275,372 | Ordinary shares denominated in Renminbi | 6,275,372 | ||||
| 16011 portfolio of basic endowment insurance fund | 5,867,634 | Ordinary shares denominated in Renminbi | 5,867,634 | ||||
| Agricultural Bank of China Limited - CSI 500 Exchange Traded Index Securities Investment Fund | 5,480,994 | Ordinary shares denominated in Renminbi | 5,480,994 | ||||
| Description of connection or acting-in-concert relationship of the above shareholders | There was no connection or acting-in-concert relationship between Shenzhen Baiyeyuan Investment Co., Ltd., a controlling shareholder of the Company, and other shareholders; whether there is connection or acting-in-concert relationship among other shareholders is unknown | ||||||
| Description of the participation of the top 10 shareholders and the top 10 shareholders without selling restrictions in margin financing and securities lending and refinancing business (if any) | As of the end of the Reporting Period, the number of the shares lent from Shenzhen Baiyeyuan Investment Co., Ltd., a controlling shareholder of the Company, through participation in refinancing is 17,380,900, without any transfer of ownership. He Zhong, a shareholder, holds a total of 7,800,024 shares of the Company, including 800,000 shares held through ordinary securities accounts and 7,000,024 shares held through credit securities accounts. |
| Description of the special repurchase account among the top 10 shareholders | As of the end of the Reporting Period, the special repurchase account of the Company (special securities repurchase account of Joincare Pharmaceutical Group Industry Co., Ltd.) owned 17,459,813 shares in total, accounting for 0.91%. |
Note: Citibank, National Association is the depositary of the Company’s GDRs, the corresponding domesticbasic A Shares of GDRs shall registered under its name according to the laws; the GDRs issued by the Companyshall be not converted into A Shares from 26 September 2022 (Switzerland Time) to 23 January 2023(Switzerland Time).
III. OTHER REMINDERSOther important information that needs to be brought to the attention of investors regarding theCompany’s operations during the Reporting Period
□Applicable √N/A
IV. QUARTERLY FINANCIAL STATEMENTS(I) Audit Opinion
□Applicable √N/A
(II) Financial Statements
Consolidated Balance Sheet
30 September 2022Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | 30 September 2022 | 31 December 2021 |
| Current assets: | ||
| Monetary funds | 14,574,355,344.50 | 11,729,230,390.98 |
| Financial assets held for trading | 121,394,233.59 | 184,638,344.31 |
| Bill receivable | 1,761,732,574.61 | 1,977,286,022.02 |
| Accounts receivable | 3,348,701,858.06 | 2,853,655,551.54 |
| Receivables financing | ||
| Prepayments | 390,858,423.43 | 369,232,546.29 |
| Other receivables | 51,182,462.61 | 88,053,825.12 |
| In which: Interests receivable | 365,873.64 | |
| Dividends receivable | ||
| Inventories | 2,293,286,563.09 | 2,078,944,387.68 |
| Contract assets | ||
| Held-for-sale assets | ||
| Non-current assets due within one year | 38,498.84 | 317,381.23 |
| Other current assets | 28,941,853.23 | 83,986,214.37 |
| Total current assets | 22,570,491,811.96 | 19,365,344,663.54 |
| Non-current assets: | ||
| Debt investment | ||
| Other debt investment | ||
| Long-term receivables | 82,574.69 | 266,904.13 |
| Long-term equity investment | 1,445,516,030.89 | 1,419,349,454.84 |
| Other equity instrument investment | 1,202,246,220.39 | 1,408,882,377.42 |
| Other non-current financial assets | ||
| Investment properties | 6,191,475.43 | 6,191,475.43 |
| Fixed assets | 5,031,567,135.95 | 4,839,005,169.81 |
| Construction in progress | 914,020,725.38 | 742,998,743.75 |
| Productive biological assets | ||
| Oil & gas assets | ||
| Right-of-use assets | 41,072,299.34 | 46,774,759.69 |
| Intangible assets | 507,221,484.83 | 456,782,094.80 |
| Development expenses | 803,845,060.85 | 786,993,435.71 |
| Goodwill | 614,468,698.73 | 614,468,698.73 |
| Long-term prepaid expenses | 248,031,970.13 | 200,715,740.93 |
| Deferred income tax assets | 599,351,023.48 | 552,542,866.71 |
| Other non-current assets | 729,588,852.49 | 663,584,003.80 |
| Total non-current assets | 12,143,203,552.58 | 11,738,555,725.75 |
| Total assets | 34,713,695,364.54 | 31,103,900,389.29 |
| Current liabilities: | ||
| Short-term loans | 2,355,133,620.36 | 2,518,484,835.09 |
| Financial liabilities held for trading | 23,888,725.35 | 143,302.24 |
| Notes payable | 1,704,031,516.46 | 1,582,386,767.93 |
| Accounts payable | 875,494,946.90 | 871,553,210.51 |
| Receipts in advance | ||
| Contract liabilities | 85,390,395.48 | 234,140,702.29 |
| Payroll payable | 422,866,738.80 | 475,430,823.20 |
| Taxes payable | 356,093,489.85 | 270,618,183.41 |
| Other payables | 3,629,808,271.81 | 3,292,407,989.79 |
| In which: Interests payable | ||
| Dividends payable | 14,009,877.69 | 6,951,984.46 |
| Held-for-sale liabilities | ||
| Non-current liabilities due within one year | 19,385,099.93 | 91,576,066.33 |
| Other current liabilities | 5,977,716.75 | 15,626,224.29 |
| Total current liabilities | 9,478,070,521.69 | 9,352,368,105.08 |
| Non-current liabilities: | ||
| Long-term loans | 3,028,666,590.94 | 826,780,252.78 |
| Bonds payable | ||
| Lease liabilities | 22,778,162.56 | 25,071,794.32 |
| Long-term payables | ||
| Long-term payroll payable | ||
| Estimated liabilities | ||
| Deferred income | 458,651,827.54 | 433,543,352.40 |
| Deferred income tax liabilities | 191,906,813.07 | 208,525,905.39 |
| Other non-current liabilities | 84,000,000.00 | 78,000,000.00 |
| Total non-current liabilities | 3,786,003,394.11 | 1,571,921,304.89 |
| Total liabilities | 13,264,073,915.80 | 10,924,289,409.97 |
| Owner's equity (or shareholder's equity): | ||
| Paid-in capital | 1,927,655,269.00 | 1,907,727,908.00 |
| Other equity instruments | ||
| In which: Preferred shares | ||
| Perpetual debts | ||
| Capital reserve | 2,358,462,480.42 | 2,265,357,311.92 |
| Less: Treasury shares | 222,644,454.50 | 222,644,454.50 |
| Other comprehensive income | 37,371,610.95 | 5,387,545.97 |
| Special reserve | ||
| Surplus reserve | 649,438,942.77 | 640,821,179.08 |
| Undistributed profits | 8,150,208,360.92 | 7,223,644,166.22 |
| Total owner's equity (or shareholder's equity) attributable to the parent company | 12,900,492,209.56 | 11,820,293,656.69 |
| Minority shareholder's equity | 8,549,129,239.18 | 8,359,317,322.63 |
| Total owner's equity (or shareholder's equity) | 21,449,621,448.74 | 20,179,610,979.32 |
| Total liabilities and owner's equity (or shareholder's equity) | 34,713,695,364.54 | 31,103,900,389.29 |
Person-in-charge of theCompany: Zhu Baoguo
Person-in-charge of theCompany's accounting work:
Qiu Qingfeng
Person-in-charge of theaccounting department: QiuQingfeng
Consolidated Income StatementFrom January to September, 2022Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First three quarters (January to September) for 2022 | First three quarters (January to September) for 2021 |
| I. Total revenue | 13,011,966,738.16 | 11,933,648,988.85 |
| In which: Operating revenue | 13,011,966,738.16 | 11,933,648,988.85 |
| II. Total operating costs | 10,347,452,908.46 | 9,728,395,382.69 |
| In which: Operating costs | 4,590,752,440.39 | 4,202,628,262.24 |
| Operating tax and surcharges | 148,072,490.55 | 138,588,360.34 |
| Selling expenses | 3,893,351,191.76 | 3,820,420,328.92 |
| Administrative expenses | 813,143,493.11 | 651,003,507.97 |
| R&D expenses | 1,232,505,100.33 | 959,056,925.14 |
| Financial expenses | -330,371,807.68 | -43,302,001.92 |
| In which: Interest expenses | 95,844,022.98 | 73,581,421.29 |
| Interest income | 296,268,948.39 | 111,786,015.39 |
| Add: Other income | 142,661,731.19 | 177,015,688.29 |
| Income from investments (loss is indicated by“-”) | 48,386,584.36 | 69,260,277.50 |
| In which: Income from investments in associates and joint ventures | 52,468,548.10 | 11,789,322.81 |
| Gains from derecognition of financial assets at amortized cost | ||
| Gains from net exposure hedges (loss is indicated by“-”) | ||
| Gains from changes in fair values (loss is indicated by“-”) | -86,989,533.83 | -18,014,545.96 |
| Losses of credit impairment (loss is indicated by“-”) | -9,508,656.53 | -10,549,870.63 |
| Impairment loss of assets (loss is indicated by“-”) | -142,159,872.24 | -35,798,711.62 |
| Gains from disposal of assets (loss is indicated by“-”) | 1,121,679.66 | 18,357,859.21 |
| III. Operating profit (loss is indicated by“-”) | 2,618,025,762.31 | 2,405,524,302.95 |
| Add: Non-operating income | 4,995,275.26 | 5,662,349.74 |
| Less: Non-operating expenses | 13,738,456.89 | 19,120,502.95 |
| IV. Total profit (loss is indicated by“-”) | 2,609,282,580.68 | 2,392,066,149.74 |
| Less: Income tax expenses | 408,012,299.49 | 316,486,740.44 |
| V. Net profit (loss is indicated by“-”) | 2,201,270,281.19 | 2,075,579,409.30 |
| (I) Classified by business continuity | ||
| 1. Net profit from ongoing operation (loss is indicated by“-”) | 2,201,270,281.19 | 2,075,579,409.30 |
| 2. Net profit from discontinuing operation (loss is indicated by“-”) | ||
| (II) Classified by ownership | ||
| 1.Net profit attributable to shareholders of the parent company (loss is indicated by“-”) | 1,126,561,953.23 | 1,008,675,184.73 |
| 2.Profit and loss of minority shareholders (loss is indicated by“-”) | 1,074,708,327.96 | 1,066,904,224.57 |
| VI. Other comprehensive income, net of tax | 80,412,282.94 | -177,089,388.22 |
| (I) Other comprehensive income attributable to owners of the parent company, net of tax | 31,984,064.97 | -90,541,944.15 |
| 1. Other comprehensive income that cannot be reclassified into profit or loss | 12,029,097.03 | -55,197,967.72 |
| (1) Changes from remeasurement of defined benefit plans | ||
| (2) Other comprehensive income that cannot be reclassified into profit or loss under the equity method | 1,173,144.60 | -3,992,639.64 |
| (3) Changes in fair value of investments in other equity instruments | 10,855,952.43 | -51,205,328.08 |
| (4) Changes in fair value of the enterprise's own credit risks | ||
| 2. Other comprehensive income that will be reclassified into profit or loss | 19,954,967.94 | -35,343,976.43 |
| (1) Other comprehensive income that can be reclassified into profit or loss under the equity method | ||
| (2) Changes in fair value of other debt investments | ||
| (3) Amount of financial assets reclassified into other comprehensive income | ||
| (4) Provision for credit impairment of other debt investments | ||
| (5) Reserve for cash flow hedges | ||
| (6) Exchange differences on translation of financial statements denominated in foreign currencies | 19,954,967.94 | -35,343,976.43 |
| (7) Others | ||
| (II) Other comprehensive income attributable to minority shareholders, net of tax | 48,428,217.97 | -86,547,444.07 |
| VII. Total comprehensive income | 2,281,682,564.13 | 1,898,490,021.08 |
| (I) Total comprehensive income attributable to owners of the parent company | 1,158,546,018.20 | 918,133,240.58 |
| (II) Total comprehensive income attributable to minority shareholders | 1,123,136,545.93 | 980,356,780.50 |
| VIII. Earnings per share: | ||
| (I) Basic earnings per share (RMB/share) | 0.5983 | 0.5154 |
| (II) Diluted earnings per share (RMB/share) | 0.5971 | 0.5142 |
Person-in-charge of theCompany: Zhu Baoguo
Person-in-charge of theCompany's accounting work:
Qiu Qingfeng
Person-in-charge of theaccounting department: QiuQingfeng
Consolidated Cash Flow Statement
From January to September, 2022Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First three quarters (January to September) for 2022 | First three quarters (January to September) for 2021 |
| I. Cash flow from operating activities: | ||
| Cash received from sales of goods and rendering of services | 13,705,807,329.89 | 11,899,181,183.24 |
| Tax refunds | 219,263,256.92 | 117,304,422.29 |
| Other cash received related to operating activities | 536,180,845.96 | 357,722,261.48 |
| Subtotal of cash inflow from operating activities | 14,461,251,432.77 | 12,374,207,867.01 |
| Cash paid for goods and services | 4,180,212,054.68 | 3,161,363,236.72 |
| Cash paid to and on behalf of employees | 1,797,221,409.89 | 1,546,737,299.97 |
| Taxes paid | 1,293,188,165.95 | 1,263,867,720.70 |
| Other cash paid related to operating activities | 4,581,637,269.28 | 4,781,069,905.04 |
| Subtotal of cash outflow in operating activities | 11,852,258,899.80 | 10,753,038,162.43 |
| Net cash flow from operating activities | 2,608,992,532.97 | 1,621,169,704.58 |
| II. Cash flow from investing activities: | ||
| Cash received from withdrawal of investment | 216,970,980.42 | 110,302,936.39 |
| Cash received from investment income | 121,905,782.77 | 93,348,249.99 |
| Net cash received from disposal of fixed assets, intangible assets and other long-term assets | 1,307,684.20 | 8,684,509.74 |
| Net cash received from disposal of subsidiaries and other business units | 3,311,220.53 | |
| Other cash received related to investing activities | 13,356,765.87 | 14,765,008.34 |
| Subtotal of cash inflow from investing activities | 353,541,213.26 | 230,411,924.99 |
| Cash paid for purchase and construction of fixed assets, intangible assets and other long-term assets | 975,980,046.68 | 960,679,392.16 |
| Cash paid for investment | 37,995,968.80 | 774,000,000.00 |
| Net cash paid for acquisition of subsidiaries and other business units | ||
| Other cash paid related to investing activities | 226,494,395.22 | 5,067,470.33 |
| Subtotal of cash outflow in investing activities | 1,240,470,410.70 | 1,739,746,862.49 |
| Net cash flow from investing activities | -886,929,197.44 | -1,509,334,937.50 |
| III. Cash flow from financing activities: | ||
| Cash received from absorption of investments | 719,365,346.09 | 521,836,124.79 |
| In which: Cash received by subsidiaries from investments of minority shareholders | 324,225,000.00 | |
| Borrowings received | 5,297,022,796.00 | 2,354,753,015.63 |
| Other cash received related to financing activities | 303,958,487.50 | 34,430,100.74 |
| Subtotal of cash inflow from financing activities | 6,320,346,629.59 | 2,911,019,241.16 |
| Cash repayment | 3,504,080,892.47 | 2,282,684,146.53 |
| Cash paid for dividend and profit distribution or interest payment | 1,314,118,888.43 | 1,211,553,686.47 |
| In which: Dividends and profit paid by subsidiaries to minority shareholders | 1,314,118,888.43 | 846,741,767.14 |
| Other cash paid related to financing activities | 628,305,503.73 | 1,200,553,298.22 |
| Subtotal of cash outflow in financing activities | 5,446,505,284.63 | 4,694,791,131.22 |
| Net cash flow from financing activities | 873,841,344.96 | -1,783,771,890.06 |
| IV. Influence of exchange rate fluctuations on cash and cash equivalents | 227,244,304.84 | -20,822,588.77 |
| V. Net increase in cash and cash equivalents | 2,823,148,985.32 | -1,692,759,711.75 |
| Add: Opening balance of cash and cash equivalents | 11,697,518,141.18 | 12,122,781,311.49 |
| VI. Closing balance of cash and cash equivalents | 14,520,667,126.50 | 10,430,021,599.74 |
Person-in-charge of theCompany: Zhu Baoguo
Person-in-charge of theCompany's accounting work:
Qiu Qingfeng
Person-in-charge of theaccounting department: QiuQingfeng
Implementation of, such as new accounting standards or interpretations of standards, for the first timefrom 2022 involves adjustments to the financial statements at the beginning of the year of first-timeimplementation
□Applicable √N/A
Hereby the announcement is made.
Joincare Pharmaceutical Group Industry Co., Ltd.
26 October, 2022